<DOC>
	<DOCNO>NCT01513473</DOCNO>
	<brief_summary>This trial conduct Africa , Asia , Europe United States America ( USA ) . The aim trial investigate efficacy safety insulin degludec child adolescent type 1 diabetes mellitus .</brief_summary>
	<brief_title>A Trial Investigating Efficacy Safety Insulin Degludec Children Adolescents With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Informed consent , child assent ageappropriate , obtain trialrelated activity ( Trialrelated activity procedure would perform normal management subject ) . The parent legal representative child must sign date Informed Consent Form accord local requirement . The child , possible , parent legal representative child must sign date Child Assent Form accord local requirement Male female diagnose type 1 diabetes mellitus ( T1DM ) ( base clinical judgement support laboratory analysis per local guideline ) Ongoing daily treatment insulin ( regimen ) least 3 month prior Visit 1 ( screen ) . No OADs ( oral antidiabetic drug ) allow HbA1c ( glycosylated haemoglobin ) maximum 11 % Known suspect hypersensitivity trial product ( ) relate product Previous participation trial . Participation define randomisation Girls pregnant , breastfeed intend become pregnant Girls menarche use adequate contraceptive measure accord local requirement Known hypoglycaemic unawareness recurrent severe hypoglycaemic event judge Investigator ( trial physician ) More 1 diabetic ketoacidosis require hospitalisation within last 3 month prior Visit 1 Significant concomitant disease , except condition associate type 1 diabetes mellitus , Investigator 's opinion could interfere trial The receipt investigational drug within 1 month prior Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>